| |
| |
|
| Insider
Information: |
Tessier-Lavigne Marc |
| Relationship: |
Director |
| City: |
So San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,228,119 |
|
|
Indirect Shares
|
236,869 |
|
|
| Direct
Value |
$43,379,303 |
|
|
|
Indirect Value
|
$4,751,592 |
|
|
| Total
Shares |
2,464,988 |
|
|
| Total
Value |
$48,130,895 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 42.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pfizer Inc |
PFE |
Director |
2011-12-12 |
104 |
|
0 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2023-01-03 |
2,434 |
2013-05-06 |
0 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2013-07-24 |
101,009 |
|
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2014-12-23 |
250,000 |
|
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
1,874,572 |
2023-06-01 |
236,869 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
2,544,370 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-07 |
4 |
OE |
$18.00 |
$1,765,275 |
D/D |
94,378 |
2,638,748 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-07 |
4 |
AS |
$70.35 |
$6,639,523 |
D/D |
(94,378) |
2,544,370 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-09-13 |
4 |
AS |
$636.64 |
$8,181,827 |
D/D |
(12,750) |
2,078 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-09-13 |
4 |
OE |
$273.67 |
$3,489,293 |
D/D |
12,750 |
14,828 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-10-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
300,000 |
100,000 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-10-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
300,000 |
2,244,370 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-12-09 |
4 |
OE |
$371.40 |
$1,405,378 |
D/D |
3,784 |
5,862 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2021-12-09 |
4 |
AS |
$665.00 |
$2,516,360 |
D/D |
(3,784) |
2,078 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-12-28 |
4 |
S |
$44.37 |
$487,219 |
I/I |
(10,980) |
96,354 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-12-29 |
4 |
S |
$43.87 |
$1,408,617 |
I/I |
(32,104) |
85,650 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-12-30 |
4 |
S |
$45.13 |
$909,361 |
I/I |
(20,047) |
78,848 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
2,269 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-16 |
4 |
OE |
$374.12 |
$1,631,537 |
D/D |
4,361 |
6,630 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-16 |
4 |
AS |
$675.00 |
$2,943,675 |
D/D |
(4,361) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-17 |
4 |
AS |
$680.00 |
$5,324,400 |
D/D |
(7,830) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-17 |
4 |
OE |
$376.69 |
$2,949,483 |
D/D |
7,830 |
10,099 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-21 |
4 |
AS |
$690.00 |
$5,132,910 |
D/D |
(7,439) |
2,269 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2022-03-21 |
4 |
OE |
$380.95 |
$2,833,887 |
D/D |
7,439 |
9,708 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-03-23 |
4 |
S |
$33.40 |
$676,583 |
D/D |
(20,000) |
2,024,370 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
2,030,356 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-23 |
4 |
D |
$31.10 |
$412,076 |
D/D |
(13,250) |
2,017,106 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-24 |
4 |
D |
$30.53 |
$1,430,968 |
D/D |
(46,750) |
1,970,356 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-07-25 |
4 |
S |
$35.60 |
$712,110 |
D/D |
(20,000) |
1,950,356 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-08-23 |
4 |
AS |
$31.61 |
$632,282 |
D/D |
(20,000) |
1,930,356 |
0 |
% |
|
65 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
